T. Rowe Price Associates’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

T. Rowe Price Associates’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-38,723	Closed	-$163K	–	3038
2023 Q1	$163K	Buy	38,723 +1,130	+3%	+$5.87K	﹤0.01%	2578
2022 Q4	$226K	Buy	37,593 +1,654	+5%	+$9.03K	﹤0.01%	2487
2022 Q3	$210K	Buy	35,939 +6,900	+24%	+$43K	﹤0.01%	2524
2022 Q2	$173K	Buy	29,039 +1,639	+6%	+$8.39K	﹤0.01%	2635
2022 Q1	$128K	Sell	27,400 -5,300	-16%	-$15.8K	﹤0.01%	2806
2021 Q4	$81K	Hold	32,700	–	–	﹤0.01%	2897
2021 Q3	$96K	Hold	32,700	–	–	﹤0.01%	2855
2021 Q2	$82K	Hold	32,700	–	–	﹤0.01%	2867
2021 Q1	$95K	Buy	+32,700	New	+$107K	﹤0.01%	2785
2015 Q1	–	Sell	-396,000	Closed	-$9.35M	–	2625
2014 Q4	$9.35M	Buy	+396,000	New	+$9.16M	﹤0.01%	1343

Other funds holding CTIC

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

T. Rowe Price Associates's CTIC Position: Q2 2023 in Review

T. Rowe Price Associates sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 38,723 shares — an estimated $163K sold.

T. Rowe Price Associates first reported a position in CTIC in Q4 2014 and held it in 10 quarters. The position peaked at $9.35M in Q4 2014. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

T. Rowe Price Associates reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
T. Rowe Price Associates sold 38,723 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $163K.
T. Rowe Price Associates first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2014 and held it in 10 quarters.
T. Rowe Price Associates's CTI BioPharma Corp. (DE) Common Stock position peaked at $9.35M in Q4 2014.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.